Abstract
Aim: Provide real-world data on palbociclib as evidence of effectiveness in patient populations from routine clinical practice. Methods: This was a retrospective, observational cohort study of patients with HR+/HER2- metastatic breast cancer treated with palbociclib plus aromatase inhibitor (AI) or AI alone as first-line therapy within the US Oncology Network. Results: Patients treated with palbociclib plus AI (n=838) versus AI alone (n=450) had a numerically longer median overall survival (42.1 vs 35.7months; hazard ratio [HR] =0.90 [95% CI: 0.75-1.07]; p=0.117) and a significantly extended real-world progression-free survival (21.0 vs 15.7months; HR=0.75 [95% CI: 0.64-0.88]; p=0.0002) after normalized inverse probability treatment weighting. Conclusion: These real-world results support the use of palbociclib plus AI as first-line treatment in routine clinical practice for patients with HR+/HER2- metastatic breast cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
